NASDAQ:SABS • US78397T2024
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for SAB BIOTHERAPEUTICS INC (SABS).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-11 | Chardan Capital | Maintains | Buy -> Buy |
| 2026-03-10 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2026-01-07 | UBS | Initiate | Buy |
| 2025-12-19 | Guggenheim | Initiate | Buy |
| 2025-12-18 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-11-17 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-09-19 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-09-17 | Leerink Partners | Initiate | Outperform |
| 2025-08-08 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-07-22 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-05-15 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-04-01 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-04-01 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-29 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-01-29 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-07 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-10-09 | Craig-Hallum | Initiate | Buy |
| 2024-09-12 | Oppenheimer | Reiterate | Outperform -> Outperform |
| 2024-09-09 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-08-28 | Oppenheimer | Initiate | Outperform |
| 2024-08-12 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-08-12 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-06-07 | Brookline Capital | Initiate | Buy |
| 2024-05-21 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-05-21 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 23.904M -60.73% | 2.239M -90.63% | 1.322M -40.94% | -100.00% | 127.5K | 7.025M 5,409.80% | 79.922M 1,037.68% | 218.94M 173.94% | 376.72M 72.07% | 598.4M 58.84% | 810.9M 35.51% | ||
| EBITDA YoY % growth | -25.627M -115.26% | -34.322M -33.93% | -38.018M -10.77% | -47.287M -20.40% | -70.125M -53.21% | -81.243M -15.85% | -83.12M -2.31% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -28.796M -114.99% | -37.975M -31.88% | -42.811M -12.73% | -47.307M -14.12% | -69.635M -42.54% | -87.526M -25.69% | -104.487M -19.38% | -111.744M -6.95% | -43.165M 61.37% | -29.002M 32.81% | 114.95M 496.35% | 239.36M 108.23% | |
| Operating Margin | -120.47% | -1,696.07% | -3,237.33% | N/A | N/A | -68,648.00% | -1,487.36% | -139.82% | -19.72% | -7.70% | 19.21% | 29.52% | |
| EPS YoY % growth | -2.70 -37.51% | -7.28 -169.63% | -3.74 48.68% | -0.46 42.45% | -0.80 62.76% | -0.48 40.64% | -0.46 3.00% | -0.29 38.05% | 0.64 325.00% | N/A | N/A | N/A |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.23 58.41% | -0.25 77.07% | -0.22 -49.60% | -0.19 44.63% | -0.08 64.96% | -0.08 67.35% | -0.09 59.09% | -0.08 57.89% |
| Revenue Q2Q % growth | ||||||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -15.741M -47.02% | -16.967M -75.51% | -17.915M -42.02% | -18.992M -20.43% | -16.065M -2.06% | -16.83M 0.81% | -17.595M 1.79% | -18.36M 3.33% |
All data in USD
14 analysts have analysed SABS and the average price target is 9.69 USD. This implies a price increase of 175.28% is expected in the next year compared to the current price of 3.52.
SAB BIOTHERAPEUTICS INC (SABS) will report earnings on 2026-05-07.
The consensus EPS estimate for the next earnings of SAB BIOTHERAPEUTICS INC (SABS) is -0.23 USD and the consensus revenue estimate is 0 USD.
The consensus rating for SAB BIOTHERAPEUTICS INC (SABS) is 85.7143 / 100 . This indicates that analysts generally have a positive outlook on the stock.